

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/093090 A1

(51) International Patent Classification⁷: C12Q 1/68, C07H 21/04, C12Q 1/48, A61K 31/711, A61P 35/00

(74) Agent: MBM & CO.; P.O. Box 809, Station B, Ottawa, Ontario K1P 5P9 (CA).

(21) International Application Number: PCT/CA2005/000347

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 7 March 2005 (07.03.2005)

(30) Priority Data: 60/556,733 26 March 2004 (26.03.2004) US

(71) Applicant (*for all designated States except US*): SARISSA INC. [CA/CA]; 121 Timber Drive, London, Ontario N6K 4A2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): VINCENT, Mark, D. [CA/CA]; c/o London Regional Cancer Center, 790 Commissioners Road East, London, Ontario N6A 4L6 (CA). KOROPATNICK, D., James [CA/CA]; c/o London Regional Cancer Center, 790 Commissioners Road East, London, Ontario N6A 4L6 (CA).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/093090 A1

(54) Title: ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF IN IMPROVING CANCER TREATMENT STRATEGIES

(57) Abstract: The present invention provides methods of using antisense oligonucleotides against thymidylate synthase to identify potential drug targets for new cancer therapies and to improve current cancer therapies. The oligonucleotides of the invention are complementary to thymidylate synthase mRNA and affect expression of thymidylate synthase and at least one other gene.